EDITORIAL
Reference centers for interstitial lung diseases
 
More details
Hide details
1
Academic Department of Pneumonology, Interstitial Lung Diseases Unit, Medical School, National and Kapodistrian University of Athens; Hospital for Diseases of the Chest “Sotiria”, Greece
CORRESPONDING AUTHOR
Demosthenes Bouros   

Medical School, University of Athens, Academic Department of Pneumonology, Hospital for Diseases of the Chest “Sotiria”, 152 Messogion Ave. , Athens 11527, Greece
Publication date: 2021-06-17
 
Pneumon 2016;29(1):15–17
 
CONFLICTS OF INTEREST
We have no conflict of interest to declare
 
REFERENCES (21)
1.
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J RespirCrit Care Med 2002;165:277-304.
 
2.
Travis WD, Costabel U, Hansell DM, et al; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2013; 188:733–48.
 
3.
Raghu G, Collard RH, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
 
4.
Raghu G, Chen SY, Yeh WS et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014;2:566-72.
 
5.
Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 2015;46:795-806.
 
6.
Bouros D. Idiopathic Pulmonary Fibrosis: The dawn of a new era. Pneumon 2014;27:117.
 
7.
Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet 2011; 377:1727-9.
 
8.
King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083–92.
 
9.
Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071–82.
 
10.
Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77.
 
11.
Bouros D. Current therapy of idiopathic pulmonary fibrosis: primum non noccere! Pneumon 2012;25:256-8.
 
12.
Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199–203.
 
13.
Lynch DA, Godwin JD, Safrin S, et al; Idiopathic Pulmonary Fibrosis Study Group. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J RespirCrit Care Med 2005; 172:488–93.
 
14.
Watadani T, Sakai F, Johkoh T, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 2013;266:936-44.
 
15.
Walsh SL, Calandriello L, Sverzellati N, et al. Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax 2016;71:45-51.
 
16.
Nicholson AG, Addis BJ, Bharucha H, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004;59:500-5.
 
17.
Kreider ME, Hansen-Flaschen J, Ahmad NN, et al. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann Thorac Surg 2007;83:1140–44.
 
18.
Chida M, Ono S, Hoshikawa Y, Kondo T. Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. Eur J Cardiothorac Surg 2008;34:878–81.
 
19.
Tzilas V, Bouros D. Inherent weaknesses of the current ICD coding system regarding idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1194-6.
 
20.
Kaunisto J, Kelloniemi K, Sutinen E, et al. Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulm Med 2015;15:92.
 
21.
Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011;184:842–7.
 
eISSN:1791-4914
ISSN:1105-848X